Exagen inc. announces closing of public offering of common stock, including full exercise of underwriters' option to purchase additional shares

San diego, march 25, 2021 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $16.25 per share. the gross proceeds to exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $69.1 million.
XGN Ratings Summary
XGN Quant Ranking